Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine space, has entered into a strategic collaboration with Germany’s Boehringer Ingelheim to advance the development of companion diagnostics (CDx). The partnership is aimed at identifying non-small cell lung cancer (NSCLC) patients who are most likely to respond positively to targeted therapies. While the financial details of the agreement were not disclosed, the collaboration signifies a significant step in the field of personalized medicine.
AmoyDx, listed on the Shenzhen Stock Exchange, has an impressive roster of partners, including industry giants such as AstraZeneca, BeiGene, and Eli Lilly. This new alliance with Boehringer Ingelheim further cements AmoyDx’s position as a key player in the global diagnostics market, focusing on the development of personalized treatment strategies for cancer patients.- Fineline.com
